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Abstract:
Fluorescent semiconductor quantum dots (QDs) have attracted tremendous attention over the last
decade. The superior optical properties of QDs over conventional organic dyes make them
attractive labels for a wide variety of biomedical applications, whereas their potential toxicity
and instability in biological environment has puzzled scientific researchers. Much research effort
has been devoted to surface modification and functionalization of QDs to make them versatile
probes for biomedical applications, and significant progress has been made over the last several
years. This review article aims to describe the current state-of-the-art of the synthesis,
modification, bioconjugation, and applications of QDs for in vivo targeted imaging. In addition,
QD-based multifunctional nanoprobes are also summarized.

Keywords:

quantum

dots

(QDs),

nanoparticles

(NPs),

molecular

nanotechnology, multimodality imaging, near-infrared fluorescence (NIRF)

imaging,

cancer

1. INTRODUCTION
Over the last two decades, many imaging tools have been applied in biological and
biomedical research, such as magnetic resonance imaging (MRI) [1-3], computed tomography
(CT) [4,5], positron emission tomography (PET) [6-10], single-photon emission computed
tomography (SPECT) [11], fluorescence/bioluminescence [12-15], ultrasound (US) [16], as well
as multimodality approaches that can combine the benefit of various imaging techniques [17-20].
With the size comparable to biological molecules, but orders of magnitude smaller than human
cells, nanoparticles (NPs) can offer unprecedented interactions with biomolecules both on the
surface of and inside the cells which may revolutionize disease diagnosis and treatment. Upon
incorporation of certain targeting moieties, these NPs can be employed to interrogate specific
molecular and cellular events in living systems. For molecular imaging applications, a variety of
NPs including magnetic NPs [21-23], semiconductor quantum dots (QDs) [24-28], carbon
nanotubes [29-31], gold NPs [32-34], and graphene-based nanomaterials [35-37] have been
investigated and are expected to play increasingly more important roles in preclinical/clinical
research in the future. Among these NPs, semiconductor QDs have attracted significant attention
for optical imaging applications, because of their exceptional properties and many advantages
over conventional organic dyes [38].
In general, QDs are semiconductor nanocrystals composed of II-IV (e.g. CdSe and CdTe) or
III-V (e.g. InP and InAs) groups of elements. At the nanoscale, the band-gap energy in
semiconductors depends not only on the composition of the elements, but also on the particle

size [39-42]. Such size dependence, defined as the “quantum confinement effect”, gives rise to
unique optical and electronic properties of QDs. Previous reports have demonstrated that by
varying the composition and particle size, QDs with a wide range of absorption and emission
wavelengths from the visible to the near-infrared (NIR) region can be synthesized [43-45]. A
number of features make QDs highly attractive for fluorescence imaging, such as wide
absorption range, narrow and symmetric emission spectra, high quantum yields (QY; up
to >90%), long fluorescence lifetime (> 10 ns), large effective Stokes shift (> 200 nm), and high
resistance to photobleaching and chemical degradation [38]. The small size and high QY endow
QDs with high sensitivity, making them suitable for single molecule tracking. The combination
of size-tunable fluorescence, large Stokes shifts, and narrow emission spectrum makes it possible
to separate the fluorescence signals from different QDs for multiplexed imaging. Because of the
high photostability, QDs have also been widely used for long-term imaging studies [46].
Although QDs have many advantages in imaging and spectroscopy, as mentioned above,
many barriers exist that can hinder the broad use of QDs for bioimaging applications [47]. For
example, the potential toxicity caused by the release of heavy metal ions remains a major
concern for QD-based agents [48-50]. In addition, pH-sensitive photoluminescence and
prolonged retention in animal studies are also undesirable characteristics that need to be
overcome [51-53]. To address these issues, decorating the surface of QDs with biocompatible
molecules such as polymers, liposomes, or inorganic silica have been investigated [54-56]. To
achieve specific targeting, QDs need to be conjugated to targeting ligands such as peptides,

proteins, nucleotides, among others. For in vivo imaging applications, the following factors need
to be taken into account when designing the probes: potential toxicity at the effective doses for
imaging, interference with or from normal biology/physiology, circulation lifetime, optimal
excitation/emission wavelength for sufficient tissue penetration of signal, chemistry for
ligand-conjugation and avoiding non-specific trapping, cost effectiveness, etc.
In this review article, we will summarize the recent progress in the use of QD-based
nanoprobes for imaging applications, in particular molecularly targeted imaging in animal
models. First, we will give a brief overview of the synthesis and surface modification strategies
which can render QDs suitability for biomedical applications. Next, we will discuss in detail the
use of QD-based agents for in vivo targeted imaging. Various examples of QD-based
multifunctional nanoprobes for in vivo dual-modality imaging will also be illustrated. Lastly, we
will discuss the challenges and future directions for applications of QDs in the biomedical arena.

2. SYNTHESIS AND SURFACE MODIFICATION OF QDS
2.1. Synthesis of QDs
Since the first report of QD synthesis about three decades ago [39], a variety of synthetic
methods have been developed for the preparation of QDs. Based on the different media used,
these methods can be broadly classified into two types: the organometallic route [57-60] and
aqueous synthesis [61-63]. In a typical organometallic synthesis of QDs, a solvent with high
boiling point and high coordinating capability to both metal and chalcogen elements is used,

such as trioctylphosphine oxide (TOPO). QDs synthesized in these organic solvents possess
nearly perfect crystal structures, and thus high fluorescence QY. Narrow size distribution is
another advantage for QDs prepared via this route. However, the hydrophobic surface of QDs
synthesized using this method is a major obstacle for biological applications. Many strategies
such as ligand-exchange and coating with a water-soluble shell have been adopted to change the
surface properties of QDs, however at the cost of significant loss in fluorescence signal. Another
disadvantage of the organometallic route is the costly and laborious synthetic process.
In contrast, aqueous synthesis, with the advantages of improved simplicity/reproducibility
and less toxicity, has gradually become a preferred option, despite the lower QY and broader size
distribution [64,65]. For example, hydrophilic thiol-capped QDs are more suitable for biomedical
applications because of their higher stability and better compatibility in biological environment
compared to those prepared in organic solvent. Recently, various methods have been reported for
the synthesis of thiol-capped QDs, including hydrothermal synthesis, ultrasonic methods, and
those that use illumination or microwave irradiation [66-69].
The composition, size, and shape of QD core are essential to their photoluminescence
emission range, which can be tuned from visible to the NIR range. In addition, the cores of QDs
are typically coated with another semiconductor shell composed of materials with lower toxicity
and wider band-gap (e.g. ZnS) [70,71]. The presence of such a shell can not only improve the
photoluminescence properties and passivate the surface traps, but also prevent the leaching of the
highly toxic heavy metal ions from the QDs [72].

To date, CdSe/ZnS [25,73-80] and CdTe/ZnS [81-83] QDs are among the most widely
investigated QDs for in vivo imaging, partly due to their commercial availability and mature
synthetic procedure. Meanwhile, there are also many studies using CdTe/CdS, CdHgTe, and PbS
QDs [84-87], which are attractive for in vivo applications because of their NIR emission. To
avoid the use of Cd, since it is one of the most toxic elements, many groups have reported the
synthesis and evaluation of InAs/InP/ZnSe [26,88], CuInS2/ZnS [89,90], CuInSe/ZnS [91], and
silicon QDs [92], which will be discussed in more detail in the following text. Recently,
photoluminescent carbon-based NPs have also attracted significant attention [93]. Prepared by
laser ablation or electrochemical oxidation of carbon targets [94,95], these luminescent carbon
NPs are also subjected to the quantum confinement effects hence are called carbon QDs or
C-dots. The strong sustained fluorescence of these C-dots in mice, together with their
biocompatibility and non-toxic features, make C-dots an exciting new class of probes for optical
imaging [96].

2.2. Surface Modification of QDs
Surface modification of QDs can improve the aqueous solubility, especially for those
synthesized via the organometallic route, as well as protect them from degradation and
fluorescence quenching. In addition, certain surface modification (e.g. with polyethylene glycol
[PEG]) can also help to reduce non-specific uptake in normal organs and provide functional
groups for further bioconjugation.

PEG coating, because of its well-known biocompatibility and mature chemistry, is one of the
most commonly used strategies for surface modification of QDs. Many literature reports have
shown that PEG coating can change the biodistribution of QDs in animals [97,98]. For example,
All-Jamal et al. reported that PEG-lipid coated QDs exhibited much longer blood circulation
half-life than the unmodified QDs after systemic administration [97]. In another study, it was
demonstrated that PEGylation can reduce the uptake of QDs into organs of the
reticuloendothelial system (RES), such as the liver and spleen [98].
Surface modification of QDs with a combination of PEG and other polymers has also been
investigated. In an early study, Gao et al. reported the use of an ABC triblock copolymer in
addition to PEG for QD coating, aiming to minimize the aggregation and fluorescence loss of
QDs when they are stored in physiological buffer or injected into live animals [25]. Various
experiments in cells and animal models confirmed the good stability and brightness of these QDs.
In another report by Zintchenko et al., a new type of quantoplexes incorporating NIR-emitting
CdTe QDs, polyethylenimine (PEI), and plasmid DNA (pDNA) were assembled [99]. Upon
intravenous injection, the quantoplexes accumulated rapidly in the lung, liver, and spleen, and
the fluorescence signal could be detected for at least a week. Tracking of these quantoplexes
immediately after intravenous injection revealed a rapid redistribution from the lung to the liver,
which was dependent on the PEI topology and the quantoplex formulation. In addition, a similar
quantoplex was also assembled where the PEI was replaced by PEG-PEI conjugate, which
exhibited passive tumor accumulation in nude mice bearing subcutaneous tumors. Using a solid

dispersion technique, hydrophobic PCDA (10,12-pentacosadiynoic acid) was incorporated to
assemble QDs-loaded micelles [100]. In this design, both PEG-PCDA and PCDA-Herceptin
conjugates participated in the micelle assembly, which was subjected to intra-micellar
cross-linking between PCDAs upon UV irradiation. Non-invasive fluorescent imaging showed
that with Herceptin as the targeting ligand for human epidermal growth factor receptor 2 (HER2),
these QD-loaded micelles exhibited high anti-tumor activity and selective toxicity, which led to a
marked reduction in tumor volume.
In addition to PEG, other polymeric coatings such as poly (lactic-co-glycolic acid) (PLGA)
and liposomes have also been explored [84,101,102]. In the report on QD-PLGA assembly, in
vivo experiments demonstrated the increased stability of QD-entrapped nanospheres, between
100 and 200 nm in size, against photooxidation and photobleaching [101]. In another report, the
QD-drug-liposome hybrid was found to exhibit greater uptake in mouse brains and lower uptake
in the heart and liver compared to free QDs [102]. Recently, an amphiphilic polymer with
hydrophobic inner core, termed as N-succinyl-N’-octyl nanomicelles (SOC), was used to
incorporate oil-soluble PbS QDs for subsequent long-term tracking in vivo [84].
Inorganic silica is a class of highly biocompatible material that is regularly used as a food
additive. Encapsulating QDs within silica can provide a hydrophilic surface and facilitate the
incorporation of various functional groups such as carboxyl, amine, and thiol groups for further
bioconjugation [103,104]. Furthermore, silica shell can prevent the release of toxic QD
components into the biological environment [72,105]. Although very few silica-coated QDs have

been reported for in vivo targeted imaging to date, there are several studies focusing on the
toxicity and biodistribution assessment. In one report, liver and kidneys were found to be the
main target organs for silica-coated QDs (QD-SiO2) [106]. It was suggested that QD-SiO2 were
metabolized via three pathways according to their distinct aggregated states in vivo. A fraction of
QD-SiO2 kept their original form and could be filtered by glomerular capillaries and excreted via
urine within five days. Most QD-SiO2, adsorbed onto proteins and aggregated into larger
particles, were metabolized in the liver and excreted via the feces. Part of the aggregates
remained in the hepatic tissue for a prolonged time period and could not be readily cleared.
When compared with commercially available QDs (Invitrogen, CA) of similar size and emission
wavelength, it was found that QD-SiO2 exhibited a different biodistribution pattern [107].The
commercially available QDs from Invitrogen showed predominant liver and spleen uptake
shortly after intravenous injection, whereas QD-SiO2 exhibited much lower liver and spleen
uptake but higher kidney uptake, blood retention, and partial renal clearance.

2.3. Strategies for Conjugation of QDs with Biomolecules
To effectively recognize and enable non-invasive imaging of specific molecular targets in
various organisms, QDs need to be conjugated with ligands that can specifically bind to or
interact with the target of interest [108,109]. Taking into account the surface properties of QDs
and the functional groups within the selected targeting ligands, a number of different conjugation
strategies can be employed.

Two general approaches can be adopted for QDs with hydrophobic surfaces, which are
typically prepared via the organometallic route. These QDs need to be first rendered hydrophilic
through either surface ligand exchange [90,110] or interaction with amphiphilic polymers [111].
Subsequent conjugation of biomolecules to the QDs can be achieved during the ligand exchange
step by introducing thiolated biomolecules, which is quite straightforward to obtain QD
bioconjugates. However, there are many concerns about the stability and luminescent properties
of the resulting QD bioconjugates. For those QDs with amphiphilic polymer as the surface cap, a
step of coupling the biomolecules to the polymer is needed [112]. With hydrophilic surfaces,
these QDs share similar conjugation strategies with the QDs synthesized via the aqueous route.
Based on the functional groups on the QD surface, different reactions can be used for surface
conjugation of QDs (Fig. (1)).
Ethyl(dimethylaminopropyl) carbodiimide (EDC), one of the most widely used coupling
reagents for amide bond formation between carboxylic acid and amino groups, has been
commonly used for surface modification of QDs (Fig. (1A)) [113]. It has also been used to
produce QD-streptavidin conjugates for subsequent binding of biotinylated molecules [114].
However, EDC coupling can cause non-specific crosslinking, since there can be multiple
carboxylic acid groups and amino groups in a single biomolecule, which may lead to a loss of
bioactivity especially when the carboxylic acid and/or amino groups are involved in the
biological function. Compared to EDC coupling, the thiol-maleimide reaction is more specific,
since typically only the thiol is on the biomolecule but not the maleimide. For example, amino

groups on the QD surface can be converted to maleimide by reaction with a crosslinker,
succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), which is then
conjugated to thiolated peptides, cysteine-tagged proteins, or partially reduced antibodies via the
thiol-maleimide reaction (Fig. (1B)).
Another commonly used strategy for functionalization of QDs is through the
(strept)avidin-biotin interaction, which is attractive because of its high affinity and specificity
[115-117]. This method relies on either direct binding between streptavidin-functionalized QDs
with biotinylated proteins/peptides (Fig. (1C)), or the use of avidin as a bridge between
biotinylated QDs and biomolecules. Metal-histidine binding has also been investigated for
surface modification of QDs, in which nickel nitrilotriacetic acid (Ni-NTA, a compound widely
used for isolation and purification of proteins that contain histidine tags) groups were introduced
[118-120]. For example, QDs can be modified with Ni-NTA groups via EDC coupling, and
subsequent metal affinity interactions can allowed a stoichiometry-controlled binding of this
complex to oligohistidine-tagged proteins (Fig. (1D)).
Besides the abovementioned strategies, electrostatic interactions have also been used for
conjugating amine-containing dihydrolipoic acid (DHLA ) derivative -modified QDs with
hyaluronic acid [121]. In addition, several protein-mediated strategies have been reported for
bioconjugation of QDs, and one of which involves a commercially available engineered
haloalkane dehalogenase called the HaloTag protein (HTP) [122,123]. HTP in its native form can
covalently bind to a synthetic HaloTag ligand (HTL) through the formation of an ester bond

between the chloroalkane within the HTL and the Asp106 residue of the protein, as shown in Fig.
(2A). A critical mutation in the catalytic triad (His272 to Phe) of HTP can cease further hydrolysis
of the newly formed ester bond between HTP and HTL, thereby leading to permanent linkage of
the HTL to HTP. In a report by Zhang et al. [124], an engineered Renilla luciferase (Luc8) was
genetically fused to the N terminus of HTP and expressed to obtain the fusion protein HTP-Luc8.
After conjugating QDs with a HTL, irreversible covalent binding between the HTL-conjugated
QDs and HTP-Luc8 led to close proximity of Luc8 and QDs and subsequent bioluminescence
resonance energy transfer (BRET, Fig. (2A)), which can have many potential applications.
In an intriguing report, intein-mediated protein splicing (a process that takes place after
mRNA has been translated into a protein) was used for surface modification of QDs for
multiparameter imaging of cellular function [125]. Typically composed of three segments:
N-extein, intein, and C-extein, intein can also excise itself and rejoin the remaining portions
(N-extein and C-extein) with a peptide bond. In this study, various proteins were genetically
tagged with the N-terminal half of a split intein (IN) or the C-terminal half (IC), whereas the
complementary half of the intein was biotinylated and conjugated to streptavidin-coated QDs
[125]. Intein-mediated splicing led to simultaneous, site-specific conjugation of QDs to multiple
protein targets, which opened up new possibilities for bioimaging applications (Fig. (2B)).

3. IN VIVO TARGETED IMAGING WITH QDS
Different from passive targeting, which typically depends on the enhanced permeability and

retention (EPR) effect for accumulation in the tumor [1,126,127], active targeting can be
achieved by attaching various targeting ligands to QDs for recognition of specific cell surface
molecules or proteins. A wide variety of targeting ligands have been investigated for in vivo
targeted imaging with QDs, as we discuss in detail below.

3.1. In Vivo Kinetics of QDs
An ideal fluorescence probe for non-invasive in vivo targeted imaging should satisfy several
requirements, which include sufficiently long circulating lifetime, minimal non-specific uptake
in the RES, sustained fluorescence within the timeframe of a given study, high biocompatibility
and low toxicity, among others. A large number of literature reports have indicated that particle
size and surface coating are both important factors that can affect the in vivo behavior of QDs
[48,54,98,106,128-131].
In an early report, QDs with different surface coatings were investigated with fluorescence
imaging in living mice [128]. It was found that the circulating lifetime of QDs depends on the
chain length of the surface PEG coating. When QDs were coated with 5 kDa methoxyl-PEG, the
circulation half-life was more than 1 h, compared to less than 12 min for QDs with shorter PEG
coating. In addition, PEG coating also allowed for fluorescence detection of QDs for at least four
months in vivo after intravenous injection. In a later report, it was found that QDs of different
sizes have different clearance pattern in mice [129]. As shown in Fig. (3), fluorescence signal
from QDs of 4.36 nm in diameter was mainly found in the bladder at 4 h after intravenous

injection. However, at the same time point, QDs of 8.65 nm in diameter accumulated primarily in
the lung, spleen, and liver, indicating a different excretion pattern (i.e. hepatobiliary). It was
concluded that to achieve efficient urinary excretion and elimination of QDs, the overall size
should be strictly controlled under 5.5 nm. Another possibility is to use biodegradable QDs that
can be broken down into renal clearable components, which may be developed in the future. In
another study, Praetner et al. provided experimental evidence for faster deposition of
carboxyl-coated QDs over amine-coated or PEG-coated QDs in various tissues, which might be
attributed to the interactions between carboxyl-coated QDs and capillary endothelium [132].

3.2. Peptide-Conjugated QDs
Peptides are desirable targeting ligands for NPs because of their small sizes, hence a large
number of peptides can be attached to a single NP such as QD to enhance the avidity and
specificity. Other advantages of peptides include ease of synthesis, low immunogenicity, and
tolerance to a variety of reaction conditions, among others. The first report on in vivo
investigation of peptide-conjugated QDs appeared more than a decade ago [73], in which three
peptides were evaluated for in vivo targeting of CdSe/ZnS QDs. Subsequently, the
arginine-glycine-aspartate (RGD) peptide has been widely used in QD-based research because of
its high affinity for integrins αVβ3 and αVβ5 [79,81,88,133,134]. Integrin αVβ3 is overexpressed on
the surface of angiogenic endothelial cells and certain tumor cells [135,136], which makes it an
attractive target for QD-based nanoprobes since extravasation is not required to achieve tumor

contrast. The first in vivo targeted imaging using peptide-conjugated QDs was reported in 2006
[81]. As shown in Fig. (4), fluorescence signal in the integrin αVβ3-positive U87MG tumors
could be observed shortly after intravenous injection and peaked at a few hours post-injection,
indicating effective integrin αVβ3 targeting of RGD-conjugated QD705 (with peak emission at
705 nm in the NIR range) in living mice. Detailed histological examination of the tumor tissue
revealed that targeting was vascular integrin αVβ3 specific with little extravasation. Over the last
several years, many studies from other research groups have also demonstrated that RGD
peptide-conjugated QDs could exhibit highly specific tumor targeting and reduced accumulation
in the lung, kidney, and heart in mice models [86,137-140].
RGD peptides have been conjugated to Cd-free QDs [88,92,140], which have much lower
potential toxicity and may find broader biomedical applications for future clinical translation.
For example, PEGylated InAs/InP/ZnSe QDs were conjugated to either RGD or RAD
(Arg-Ala-Asp) peptides and compared, which showed much higher tumor uptake for
RGD-conjugated QDs than RAD-conjugated QDs [88]. In another study, RGD peptides were
conjugated to PEGylated silicon QDs (SiQD), which were successfully used for in vivo tumor
targeting, sentinel lymph node mapping, and multiplex NIR imaging (Fig. (5)) [92]. Recently,
InP/ZnS QDs were first coated with biocompatible dendron for a pilot toxicity evaluation in mice
[140], which had not only low toxicity at the dose tested but also enhanced passive targeting to
tumors. After conjugation to RGD peptides, significantly higher tumor uptake and longer
retention at the tumor sites was observed compared to non-targeted dendron-coated QDs.

3.3. Proteins as Targeting Ligands for QDs
3.3.1. Antibodies
Antibodies are a class of diverse and widely used specific ligands for targeted imaging and
therapy. In 2004, Gao et al. reported the conjugation of QDs to a monoclonal antibody
recognizing the prostate-specific membrane antigen (PSMA) [25], which was investigated for
active tumor targeting in xenograft-bearing mice. Subsequently, several other antibodies have
also been conjugated to QDs and tested for tumor targeting in vivo, such as an anti-AFP
(alpha-fetoprotein) antibody and Herceptin (anti-HER2) [74,100,141]. In a comparison study, the
AVE-1642 antibody that binds to the insulin-like growth factor 1 reporter (IGF1R, an emerging
targeting for cancer imaging and therapy [142]) was used as the targeting ligand for both QDs
and AlexaFluor 680 [143]. Whole-body imaging of tumor-bearing mice indicated much higher
tumor uptake of AVE-1642-AlexaFluor 680 than the AVE-1642-QD conjugate, which is more
likely localized to the RES and engulfed by macrophages.
Mesothelin, a tumor differentiation antigen, is normally expressed on the mesothelial cells
lining the pleura, peritoneum, and pericardium [144]. Although the biological functions of
mesothelin remain to be fully elucidated, overexpression of mesothelin has been found in several
human cancer types such as malignant mesothelioma, pancreatic, ovarian, and lung
adenocarcinoma. In addition, limited expression of mesothelin in normal tissues makes it highly
attractive for specific tumor targeting [144]. In one report, CdTe/ZnS QDs were encapsulated

into carboxylated amphiphilic triblock polymer F127 (F127COOH) micelles, which were
conjugated to an anti-mesothelin antibody (Me) for tumor targeting in vivo [82]. Non-invasive
imaging of tumor-bearing mice showed that Me-F127COOH-QD micelles accumulated at the
pancreatic tumor site soon after intravenous injection (Fig. (6)).
The epidermal growth factor receptor (EGFR) is another extensively studied transmembrane
protein, which has a high degree of homology with HER2 [145,146]. Studies have shown that
~90% of oral squamous cell carcinoma (OSCC) and head and neck squamous cell carcinoma
(HNSCC) expresses EGFR at a very high level [147,148]. Therefore, anti-EGFR antibodies have
attracted significant interest for imaging and therapy of OSCC and HNSCC. For example, an
anti-EGFR monoclonal antibody was conjugated to QD800, which enabled clear in-situ and in
vivo imaging of HNSCC [149]. An anti-EGFR antibody was conjugated to Au:CdHgTe QD840
in another study [86], where QD800-RGD and QD820-anti-CEACAM1 (carcinoembryonic
antigen-related cell adhesion molecule-1) conjugates were also synthesized and used together
with QD840-anti-EGFR for in vivo tumor targeting in human lung adenocarcinoma xenografts. It
was demonstrated that all three tumor markers (EGFR, integrin αVβ3, and CEACAM1) could be
detected simultaneously, after spectral unmixing of the fluorescence signal from the three
different QD conjugates.

3.3.2. Antibody Fragments
Although many monoclonal antibodies have been used for QD-based tumor targeting and

imaging, the relatively large size of antibodies limits the number of ligands that can be attached
to the surface of each QD. In addition, it may also hamper the penetration into solid tumors,
which typically have high interstitial pressure. Alternatively, single-chain antibody fragments
(ScFv), consisting of antibody heavy- and light-chain variable domains connected by a flexible
peptide linker, is a much smaller targeting ligand than intact antibodies (25 kDa vs. 150 kDa)
which can maintain high binding affinity and specificity to the antigen [150]. In one report,
ScFvEGFR was conjugated to either QDs or magnetic iron oxide (IO) NPs for in vivo tumor
targeting and imaging in an orthotopic pancreatic cancer model [76]. Cytoplasmic localization of
ScFvEGFR-QDs was observed as fluorescent clusters, suggesting that cellular uptake of
ScFvEGFR-QDs was likely via receptor-mediated internalization. In addition, markedly reduced
uptake of ScFvEGFR-QDs was observed in the liver and spleen when compared to mice injected
with non-targeted QDs.
The glucose-regulated protein GRP78, a member of the heat shock protein family that plays
critical roles in cancer cell proliferation and oncogenesis/angiogenesis, has been shown to bind
Ca2+ and serve as an endoplasmic reticulum (ER) stress signaling regulator [151]. Recently,
ScFvGRP78 was used as targeting ligands for QD conjugation, which exhibited effective
inhibition of breast tumor growth in a mouse model [152]. c-Met, a receptor tyrosine kinase that
is strongly associated with cancer cell proliferation, migration, invasion, and tumor angiogenesis,
has attracted significant attention for targeted cancer therapy [153,154]. In a recent study, an
anti-c-Met ScFv (Ms20) was conjugated to doxorubicin-loaded PEGylated liposomes (LD) as

well as QDs [78]. In vivo tumor targeted imaging (with Ms20-QDs) and cancer therapy (with
Ms20-LD) were both successfully achieved.

3.3.3. Other Proteins
Many other proteins besides antibodies can have strong affinity to specific targets/receptors,
such as EGF (i.e. epidermal growth factor) which is the naturally occurring ligand for EGFR
[146]. In an interesting study, the distribution of EGF-QDs was compared with unconjugated
QDs through three distinct phases: tumor influx (~3 min), clearance (~60 min), and accumulation
(1-6 h) [75]. Both QDs and EGF-QDs behaved similarly at ~60 min, with comparable
non-specific and rapid tumor influx and clearance, followed by an apparent dynamic equilibrium.
However, EGF-QDs progressively accumulated in the tumors between 1 and 6 h, whereas
tumoral concentration of non-targeted QDs gradually decreased during this period. At 24 h after
injection, tumor fluorescence of either QDs or EGF-QDs was minimal and not readily detectable.
In another report, specific EGFR targeting with

99m

Tc-labeled, EGF-conjugated QDs was

reported in a breast cancer model, which allowed for monitoring of EGFR downregulation upon
therapy [155].
Successful delivery of imaging agents to the brain is highly important for both diagnosis and
treatment of central nervous system (CNS) diseases [3,156]. However, the blood-brain barrier
(BBB), formed by tight junctions within the capillary endothelium, is a major obstacle for
successful brain imaging. The wheat germ agglutinin (WGA), isolated from Triticum vulgare,

belongs to the lectin families and can bind specifically to sugar molecules such as
N-acetyl-D-glucosamine and sialic acid. By specifically recognizing sugar molecules,
WGA-conjugated QDs were shown to be capable of binding to glycosylated components on cell
surface [157,158]. After intranasal administration of WGA-QDs into BALB/c mice, WGA was
reported to enhance the binding of WGA-QDs with nasal mucosa and further improve their
uptake in the brain, which peaked at a few hours after administration (Fig. (7)). Such brain
targeting and imaging characteristics of WGA-QDs makes it a promising nanoplatform for future
imaging of various CNS diseases.

3.4. Other Ligands for In Vivo Targeting of QDs
With many advantages including small size, versatile chemistry, ease of synthesis, and lack
of immunogenicity, aptamers have recently emerged as a new class of targeting ligands for
molecular imaging and therapy [159,160]. Although aptamers have been conjugated to many
types of imaging agents such as organic dyes, magnetic NPs, and gold NPs, investigation of
aptamer-conjugated QDs is mainly in the in vitro setting [161-163]. To the best of our knowledge,
there is only one literature report on in vivo imaging and therapy of cancer using QD-aptamer
conjugates [164]. To achieve active ovarian cancer targeting, QDs was conjugated with a DNA
aptamer specific for MUC1 (mucin 1, a cell surface associated mucin which is overexpressed in
many cancer types) via EDC coupling. In addition, doxorubicin (DOX, a commonly used
anti-cancer drug) was attached to QDs via a pH-sensitive hydrazine bond, which is stable in the

circulation but can be cleaved and release DOX in acidic environment, such as after
internalization into cancer cells. In vivo imaging experiments revealed significantly higher tumor
accumulation of the targeted QD conjugate than the non-targeted QDs [164].
The
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folate-conjugated molecules. The alpha isoform of FR (FR-α) is found to be overexpressed in
many epithelial cancers but not highly expressed in normal tissues except the kidneys. Since the
affinity of FR for folic acid and folate conjugates is relatively high (Kd ~100 pM), FR-α has been
extensively investigated for tumor targeting [165], including many studies focusing on QDs
[80,83,85,89,166,167]. For example, folic acid was conjugated to PEG and subsequently
deposited onto N-acetyl-L-cysteine (NAC)-stabilized CdTeS alloyed QDs, which was
demonstrated to be capable of tumor targeting in mouse models [167]. Non-Cd-containing
CuInS2/ZnS QDs with folate-modified N-succinyl-N’-octyl chitosan (FA-SOC) micelles have
also been reported [89]. It was shown that the oil-soluble QDs could be effectively dispersed in
water and served as a platform for tumor targeting and imaging (Fig. (8)).
Hyaluronic acid (HA, also known as hyaluronan or hyaluronate), an anionic non-sulfated
glycosaminoglycan that is widely distributed throughout connective, epithelial, and neural tissues,
has been conjugated to QDs for tumor targeting since HA was shown to be associated with tumor
angiogenesis and progression [168]. Since HA can specifically bind CD44, a cell-surface
glycoprotein overexpressed in many tumor types, HA-QDs was found to have not only cancer

targeting characteristics, but also the capability for imaging lymphatic vessels [121]. In another
study, carbohydrate capped QDs were prepared by conjugating PEGylated QDs with D-mannose
or D-galactosamine, which was tested for in vitro imaging and in vivo liver targeting [169].
Captopril is a drug for treating hypertension since it can inhibit the activity of
angiotensin-converting enzyme. The in vivo behavior of captopril-conjugated QDs has been
investigated after intraperitoneal injection [77]. Strikingly, it could be delivered into the brain via
systemic circulation, suggesting that it may be a potential platform to break the BBB. Besides the
above mentioned ligands for QD conjugation, DOX has also been conjugated to QDs for
targeting alveolar macrophages and inflammation [170].

4. DUAL-MODALITY IMAGING WITH QD-BASED NANOPROBES
Tremendous advances have been made in many imaging techniques over the last decade, not
only in the clinical arena but also in preclinical imaging systems. However, no single imaging
modality is perfect to obtain all the necessary information for a given study. For instance,
fluorescence imaging faces the challenge of quantification and deep tissue penetration. MRI has
superb soft tissue contrast and good resolution but suffers from poor sensitivity. Although PET is
superior in sensitivity, quantitation, and tissue penetration, its resolution is relatively low.
Combination of multiple imaging techniques using a single probe can potentially overcome these
disadvantages and provide synergistic information. Many QD-based nanoprobes have been
designed and evaluated for these applications.

4.1. Fluorescence/MRI
In an early report, Mulder et al. coated QDs with paramagnetic gadolinium complexes and
PEGylated lipids to develop a dual-modality probe for both fluorescence imaging and MRI,
using the RGD peptides as ligands for tumor targeting [171]. However, the dual-modality probe
was only tested in vitro. Cho et al. reported a multifunctional nanocarrier composed of
fluorescent QDs, superparamagnetic IO NPs, an anti-PSMA antibody, and chemotherapeutic
agent paclitaxel [172]. Although a series of experiments confirmed the safety and
tumor-targeting capability of the nanocarrier, more studies need to be carried out in the future to
fully realize its potential for dual-modality imaging.
In 2011, Tan et al. assembled a multimodal system by co-encapsulating IO NPs and QDs in
NPs composed of poly (lactic acid)-d-α-tocopheryl polyethylene glycol 1000 succinate [173].
Without using any targeting ligands, the passive tumor targeting characteristics of the system was
demonstrated by both MRI and fluorescence imaging. Breast cancer associated antigen 1
(BRCAA1) is overexpressed in ~65% clinical specimens of gastric cancer tissues as well as
several gastric cancer cell lines. Wang et al. reported fluorescence imaging and MRI of gastric
cancer using BRCAA1 as the target [174]. By conjugating fluorescent magnetic NPs with an
antibody that binds to BRCAA1, gastric cancer targeted imaging was carried out in
tumor-bearing nude mice.
Recently, a core/shell nanoprobe was constructed for dual-modality imaging of breast cancer,

which was composed of an IO NP core and two outside layers of silica shell [175]. CdSe/ZnS
QDs (with emission peak at 600 nm) and NIR fluorescent CdSeTe/CdS QDs (with emission peak
at 780 nm) were embedded inside each silica layer to form the dual-modality agent which was
termed as MQQ-probe. After conjugation with an anti-HER2 antibody, the HER2-MQQ-probe
was injected into tumor-bearing mice. NIR fluorescence imaging demonstrated enhanced tumor
specific accumulation of HER2-MQQ-probe than the non-targeted MQQ-probe. Meanwhile,
MRI provided detailed anatomical structure of the tumor.

4.2. Fluorescence/CT
X-ray computed tomography (CT) is one of the most reliable and widely used diagnostic
tools in the clinic, which is fast, three-dimensional (3D), and has high spatial resolution [1,5].
Traditional clinical contrast agents for CT are based on iodinated molecules and compounds with
high X-ray absorption coefficient. However, these contrast agents are typically cleared very
rapidly from the blood or lymphatic vessels, which is a major disadvantage. Cardiovascular
disease is a leading cause of death worldwide, and unstable atherosclerotic plaques represent
important diagnostic targets in clinical settings for improving patient management [176,177].
Recently, fluorescent QDs were combined with iodinated molecules to create a dual-modal
contrast agent, which can potentially confer the advantages of both CT and optical imaging [178].
This nanoemulsion platform, composed of a hydrophobic iodinated oil core with QDs embedded
inside, was demonstrated to have good fluorescence and X-ray absorption abilities both in vitro

and in vivo, which can be used for targeting macrophages in atherosclerotic plaques.

4.3. Fluorescence/PET
PET is another widely used imaging technique in cancer diagnosis, staging, and evaluation of
therapeutic efficacy due to its high sensitivity, good quantitation capability, and superb tissue
penetration of signal [7,179-182]. In 2007, we reported the first targeted dual-modality
fluorescence/PET probe based on QDs, where

64

Cu was used to label QDs through the DOTA

(1,4,7,10- tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid) chelator and the RGD peptide
was employed as the targeting ligand [183]. DOTA-QD-RGD exhibited integrin αvβ3-specific
binding in cell culture and in U87MG tumor-bearing mice, which had significantly higher uptake
than the non-targeted QDs. Based on PET imaging, the U87MG tumor-to-muscle ratios for
64

Cu-DOTA-QD-RGD and

64

Cu-DOTA-QD were about 4:1 and 1:1, respectively. Excellent

linear correlation was obtained between the results measured by in vivo PET imaging and those
measured by ex vivo NIRF imaging or tissue homogenate fluorescence. Histology examination
revealed that DOTA-QD-RGD targets primarily the tumor vasculature with little extravasation,
similar as the previous report using RGD-conjugated QDs without

64

Cu-labeling [81].

Subsequently, an analogous dual-modality probe targeting the vascular endothelial growth factor
receptor (VEGFR) was also developed in a similar fashion, using VEGF as the targeting ligand
(Fig. (9)) [184]. Again, vascular specific targeting of QDs was observed with little to no
extravasation.

5. CONCLUSION AND FUTURE PERSPECTIVES
For imaging purposes, nanotechnology has touched upon every single modality of the
molecular imaging arena. Among the diverse NPs, QDs are one of the most intensively studied
which possess many inherent advantages over traditional fluorescent dyes such as significantly
higher brightness, tunable and narrow emission spectra, and increased photostability. Robust
chemistry for surface modification and targeting ligand conjugation is of critical importance to
the potential applications of QDs. Over the last decade, versatile chemistry has been developed
for synthesis and functionalization of QDs for in vitro and in vivo imaging.
Despite the remarkable progress over the last 2 decades, many obstacles exist for wide spread
use of QD-based imaging agents and potential clinical translation. For example, the potential
toxicity of QDs is still a major concern, due to the chemical composition of toxic elements such
as Cd, Se, Hg, Pb, As, etc. Although many studies have demonstrated the safety of QDs in
animal models, their long-term effect needs to be fully elucidated. To avoid these issues,
researchers have developed and investigated Cd-free QDs such as CuInS2 QDs, Si QDs, C-dots
etc., which showed promising results as described above. Another way to improve the stability of
QDs and thereby reducing the potential toxicity is through the use of optimized surface coating.
It has been demonstrated that various biocompatible polymers can effectively protect QDs from
degradation in biological environment. However, these coatings can result in significantly
increased overall size of QDs and can markedly affect the in vivo distribution, excretion, and

metabolism. Therefore, there is still a need for new surface coating strategies, with which the
overall size of QD-based nanoprobes can be strictly controlled in addition to effective protection
of QDs from biological environment. In addition, the current methods used for conjugation of
targeting ligands to QDs are suboptimal in several aspects such as low efficiency, cross-reactivity,
and strong dependence on the conditions and materials used. Development of more efficient,
specific, versatile, and straightforward conjugation strategies is needed in future research.
One of the key challenges for QD-based imaging agents is (tumor) targeting efficacy. We
believe that tumor vasculature (instead of tumor cell) targeting should be the best bet for QDs
since many of the QD-based probes reported in the literature suffered from poor extravasation
when compared with small molecules or proteins [185,186]. Aside from oncology, QD-based
agents may also find broad applications in imaging of cardiovascular diseases since the targets
are immediately accessible upon intravenous injection. The use of molecularly targeted QDs can
provide multiple advantages over small molecule-based agents, which include stronger signal
(due to the superb brightness of QDs over fluorescent dyes), enhanced binding affinity and
specificity to the target (attributed to multivalency with the presence of a large number of
targeting ligands), etc.
When using QDs for in vivo targeted imaging, the choice of targeting ligand is very
important. Among the different classes of specific ligands, peptides/small molecules are more
desirable when compared with antibodies/proteins since they can keep the overall size small, are
easier to synthesize, are more stable and resistant to harsh reaction conditions, and can fully take

advantage of the multivalency effect since more peptides/small molecules can be attached to each
QD than antibodies/proteins. Furthermore, antibodies, proteins, and antibody fragments typically
require the use of complicated biological expression systems for their production, and the
separation of conjugated QDs from antibodies/proteins can be challenging due to their similar size.
Although DNA/RNA aptamers are also easy to produce/synthesize and can have less interactions
with proteins in vivo than antibodies/proteins (i.e. lower background signal), the affinity for
individual target is usually quite low. In theory, QDs are large enough to enable multiple
targeting ligands on the surface of a single QD to simultaneously bind to multiple targets.
However, this aspect has been virtually unexplored to date. Targeting multiple different but
closely-related receptors (e.g. VEGFR and integrin αvβ3) by incorporating different targeting
ligands on the same QD, with spacers of suitable length, require robust chemistry to minimize
batch-to-batch difference and improve reproducibility.
The emerging field of multimodality imaging with QD-based nanoprobes can allow
researchers to detect the same NP with multiple imaging techniques. Cross-modality validation is
critical for providing more accurate and reliable data than with fluorescence imaging alone.
Although optical imaging can offer high sensitivity (nM level) to complement MRI (mM level)
and MRI can bypass the signal penetration limitation of optical imaging, the combination of
optical and MRI is not optimal since neither modality is quantitative. Dual-modality QD-based
agents that combine PET (which is very sensitive and highly quantitative) and optical imaging
(which can significantly facilitate ex vivo validation of the in vivo data) should be of particular

interest for future biomedical applications. For multimodal imaging employing more than two
techniques, a PET/MRI/optical agent is perhaps the most useful since such a combination
provides superb sensitivity (PET), quantitation capability (PET), excellent anatomical
information and soft tissue contrast (MRI), as well as a means for ex vivo validation (optical)
which itself can also be useful for highly sensitive imaging in certain clinically relevant scenarios
(e.g. superficial tissue, endoscopy, and intra-operative guidance).
The bright future of nanomedicine lies partly in multifunctional nanoplatforms which
combine both therapeutic components and multimodality imaging, often called “theranostics”
[187-189]. The ultimate goal of theranostic nanomedicine is that NP-based agents can allow for
efficient, specific in vivo delivery of therapeutic agents (drugs, genes, etc.) without systemic
toxicity, and the dose delivered as well as the therapeutic efficacy can be accurately measured
non-invasively over time. Much future research effort will be needed before this can be a clinical
reality. Continuous multidisciplinary efforts on the development and optimization of such
nanoplatforms will shed new light on molecular diagnostics and molecular therapy, and newer
generation of QD-based nanoprobes may have the potential to profoundly impact disease
diagnosis and patient management in the near future.
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Figure Legends

Fig. (1). Representative strategies for bioconjugation of QDs via EDC/NHS coupling (A),
thiol-maleimide reaction (B), streptavidin-biotin binding (C), and interaction between Ni-NTA
and histidine (D).

Fig. (2). (A) Modification of QDs through the use of HaloTag protein (HTP) and its ligand
(HTL). (B) In vivo conjugation of QDs to representative proteins via intein-mediated protein
splicing. Adapted from [124,125].

Fig. (3). QDs of different sizes exhibited different clearance pattern from mice after intravenous
injection. (A) Renal clearance of QD515 which has a hydrodynamic diameter of 4.36 nm. (B)
Poor clearance with high liver and lung uptake for QD574, which has a hydrodynamic diameter
of 8.65 nm. Bl: bladder; Ki: kidney; Li: liver; Lu: lung; Sp: spleen. Adapted from [129].

Fig. (4). (A) Scheme for the synthesis of QD705-RGD, in which PEG represents poly (ethylene
glycol) with molecular weight of 2000. (B) Serial in vivo imaging of U87MG tumor-bearing
mice after intravenous injection of QD705-RGD (left) or QD705 (right). QD fluorescence is
color coated red and mouse autofluorescence is color coded green. Arrows indicate tumors.
Adapted from [81].

Fig. (5). (A) Scheme for the synthesis and surface functionalization of SiQDs. (B) Tumor
targeting of RGD-SiQDs and non-targeted SiQDs at 40 h post-injection based on ex vivo imaging.
(C) Sentinel lymph node imaging captured the fluorescence of SiQDs in an axillary position.
Red color indicates QD fluorescence and mouse autofluorescence is shown in green. Adapted
from [92].

Fig. (6). Me-F127COOH-QD exhibited high tumor targeting efficiency (A) over non-targeted
F127COOH-QD (C) in a human pancreatic cancer model. B and D are corresponding photos of
mice in A and C. Me denotes an anti-methoselin antibody. Adapted from [82].

Fig. (7). (A) Distribution and retention of wheat germ agglutinin-conjugated QDs in the brain
after intranasal injection into mice. (B) Fluorescence signal in the brain peaks at 4 h after
injection. Adapted from [157].

Fig. (8). Schematic illustration of the preparation of fluorescently labeled QD-loaded micelles.
Adapted from [89].

Fig. (9). Positron emission tomography (PET) and optical imaging of vascular endothelial
growth factor (VEGF) receptor expression in a mouse model using a QD-based dual-modality

probe. 64Cu was used as the radiolabel and VEGF was used as the targeting ligand. Adapted from
[184].
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